A Study to Assess How the Drug Moves Through the Body, Adverse Events, and Tolerability of Oral ABBV-722 Capsules of Single and Multiple Ascending Doses in Adult Participants and Single Doses in Adult Asian Participants
← catalyst calendarSponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
95actual
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-10-29 | actual | When the study began enrolling |
| Primary completion | 2026-06-25 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-06-25 | actual | The whole study's end, after follow-up |
| First posted | 2024-11-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteer
Interventions
- Drug: ABBV-722
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants with Adverse Events Reported During Safety Evaluations
measured Up to Day 44
Maximum Plasma Concentration (Cmax) of ABBV-722
measured Up to Day 21
Time to Cmax (Tmax) of ABBV-722
measured Up to Day 21
For Parts 1 and 2: Area Under the Concentration-Time Curve (AUC) from Time 0 to Time t (AUCt) of ABBV-722
measured Up to Day 8
For Parts 1 and 2: Area Under the Concentration-Time Curve (AUC) from Time 0 to Infinity (AUCinf) of ABBV-722
measured Up to Day 8
For Part 3: Observed Plasma Concentration at the End of the Dosing Interval (Ctrough) of ABBV-722
measured Up to Day 21
For Part 3: AUC from Time 0 to the End of Dosing Interval (AUCtau) Following the First and Last Doses of ABBV-722
measured Up to Day 21
Terminal Phase Elimination Rate Constant (Beta) of ABBV-722
measured Up to Day 21
Terminal Phase Elimination Half-Life (t1/2) of ABBV-722
measured Up to Day 21
Dose Normalized Cmax
measured Up to Day 21
Dose Normalized AUCs
measured Up to Day 21
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed